Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1124/mol.114.095216 http://scihub22266oqcxt.onion/10.1124/mol.114.095216 25301784!ä!25301784 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=25301784&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 211.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Mol+Pharmacol 2014 ; 86 (6): 747-59 Nephropedia Template TP {{tp|p=25301784|t=2014. NADPH oxidases as novel pharmacologic targets against influenza A virus infection |pdf=|usr=}}{{25301784}} gab.com Text NADPH oxidases as novel pharmacologic targets against influenza A virus infection JO: Mol Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25301784 #FOAvip Influenza A viruses represent a major global health care challenge, with imminent pandemics, emerging antiviral resistance, and long lag times for vaccine development, raising a pressing need for novel pharmacologic strategies that ideally target the pathology irrespective of the infecting strain. Reactive oxygen species (ROS) pervade all facets of cell biology with both detrimental and protective properties. Indeed, there is compelling evidence that activation of the NADPH oxidase 2 (NOX2) isoform of the NADPH oxidase family of ROS-producing enzymes promotes lung oxidative stress, inflammation, injury, and dysfunction resulting from influenza A viruses of low to high pathogenicity, as well as impeding virus clearance. By contrast, the dual oxidase isoforms produce ROS that provide vital protective antiviral effects for the host. In this review, we propose that inhibitors of NOX2 are better alternatives than broad-spectrum antioxidant approaches for treatment of influenza pathologies, for which clinical efficacy may have been limited owing to poor bioavailability and inadvertent removal of beneficial ROS. Finally, we briefly describe the current suite of NADPH oxidase inhibitors and the molecular features of the NADPH oxidase enzymes that could be exploited by drug discovery for development of more specific and novel inhibitors to prevent or treat disease caused by influenza. Twit Text FOAVip NADPH oxidases as novel pharmacologic targets against influenza A virus infection ????Mol Pharmacol http://www.kidney.de/pget.php?&tw=1&pmid=25301784 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=25301784 #FOAvip English Wikipedia <ref>{{Cite pmid|25301784}}</ref> NADPH oxidases as novel pharmacologic targets against influenza A virus infection #MMPMID25301784 Vlahos R; Selemidis S Mol Pharmacol 2014[Dec]; 86 (6): 747-59 PMID25301784show ga Influenza A viruses represent a major global health care challenge, with imminent pandemics, emerging antiviral resistance, and long lag times for vaccine development, raising a pressing need for novel pharmacologic strategies that ideally target the pathology irrespective of the infecting strain. Reactive oxygen species (ROS) pervade all facets of cell biology with both detrimental and protective properties. Indeed, there is compelling evidence that activation of the NADPH oxidase 2 (NOX2) isoform of the NADPH oxidase family of ROS-producing enzymes promotes lung oxidative stress, inflammation, injury, and dysfunction resulting from influenza A viruses of low to high pathogenicity, as well as impeding virus clearance. By contrast, the dual oxidase isoforms produce ROS that provide vital protective antiviral effects for the host. In this review, we propose that inhibitors of NOX2 are better alternatives than broad-spectrum antioxidant approaches for treatment of influenza pathologies, for which clinical efficacy may have been limited owing to poor bioavailability and inadvertent removal of beneficial ROS. Finally, we briefly describe the current suite of NADPH oxidase inhibitors and the molecular features of the NADPH oxidase enzymes that could be exploited by drug discovery for development of more specific and novel inhibitors to prevent or treat disease caused by influenza. |Enzyme Inhibitors/*therapeutic use[MESH] |Humans[MESH] |Influenza A virus/*enzymology[MESH] |Influenza, Human/*drug therapy[MESH] |Macrophages, Alveolar/enzymology[MESH] |Membrane Glycoproteins/antagonists & inhibitors[MESH] |Membrane Lipids/chemistry[MESH] |NADPH Oxidase 2[MESH] |NADPH Oxidases/*antagonists & inhibitors/chemistry/physiology[MESH] |Phospholipids/chemistry[MESH]NADPH oxidases as novel pharmacologic targets against influenza A viru(epmc).pdf DeepDyve Pubget Overpricing